Biovica aims to improve the tumor diagnostic process by the use of new,
patented and scientifically based techniques. Our newest test, DiviTum®,
is an inexpensive, non-radioactive, high sensitivity assay that measures
thymidine kinase activity as a means to estimate tumor activity.

DiviTum® allows physicians to:
Detect malignancies earlier (myelomas, leukemias, solid tumors)
Personalize treatment

DiviTum® allows pharmaceutical companies to monitor the effects of
therapy rapidly and accurately.